Menu

News

Dec 10, 2024

Orthogon Therapeutics Closes Oversubscribed $5.2M Financing to Advance First Oral Therapy for BK Polyomavirus

Orthogon’s small molecule therapeutics redefine treatment possibilities for BK virus infections.
Read More
April 3, 2024

Conformation-X Therapeutics Bolts out of Stealth, Securing Over $13.5M in Funding to Propel Its Innovative Immune-Oncology Pipeline

The company announced an oversubscribed recent funding boost toward the preclinical development of its HHLA2 and IL18BP programs
Read More
July 24, 2023

Orthogon Therapeutics Celebrates Major Technical Milestone and Secures Additional $6M Toward a Pioneering Drug for BK Virus

The Company announced the development of the first antiviral to combat BK virus, one of the most common viral infections in transplant patients.
Read More
Load More

Presentations

Conformation X—Content

A structure-enabled, HHLA2 targeted, bispecific T cell engager, CFX11, demonstrates potent antigen-dependent anti-tumor activity in preclinical solid tumor models
Society for Immunotherapy of Cancer (SITC).
March 25-27, 2026

Pledge AI —Content

Picogen: A Generative AI Model That Unlocks Shallow PPI Interfaces Across Oncology Targets and Designs Novel Ligands, Including TEAD–YAP Inhibitors
American Association for Cancer Research (AACR) Journals Special Conference on AI in Cancer Research.
July 10, 2025

Orthogon Therapeutics—Content

Picogen: A Generative AI Model That Unlocks Shallow PPI Interfaces Across Oncology Targets and Designs Novel Ligands, Including TEAD–YAP Inhibitors
American Society of Nephrology (ANS). Kidney week.
November 6-9, 2025

Conformation X—Content

IL-18BP Inhibition Elicits Adaptative Checkpoint Expression and Enables Novel Immune-checkpoint inhibitor (ICI) Combinations in Colon Cancer.
Society for Immunotherapy of Cancer (SITC)
November 5-9, 2025
Linkedin Twitter